Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

InflaRx

6 Disclosed Funding Rounds $164,000,000

0 Participating Investments


Pharmaceutical, Therapeutics, Health Care, Medical

InflaRx develops new therapeutics in the field of acute and chronic inflammation.

Jena, Thuringen, Germany, Europe (DE)

Organizations in Jena in Pharmaceutical,
Organizations in Jena in Therapeutics,
Organizations in Jena in Health Care,
Organizations in Jena in Medical,
Organizations in Thuringen in Pharmaceutical,
Organizations in Thuringen in Therapeutics,
Organizations in Thuringen in Health Care,
Organizations in Thuringen in Medical,
Organizations in Germany in Pharmaceutical,
Organizations in Germany in Therapeutics,
Organizations in Germany in Health Care,
Organizations in Germany in Medical,
Organizations in Europe in Pharmaceutical,
Organizations in Europe in Therapeutics,
Organizations in Europe in Health Care,
Organizations in Europe in Medical

Investors in Jena in Pharmaceutical,
Investors in Jena in Therapeutics,
Investors in Jena in Health Care,
Investors in Jena in Medical,
Investors in Thuringen in Pharmaceutical,
Investors in Thuringen in Therapeutics,
Investors in Thuringen in Health Care,
Investors in Thuringen in Medical,
Investors in Germany in Pharmaceutical,
Investors in Germany in Therapeutics,
Investors in Germany in Health Care,
Investors in Germany in Medical,
Investors in Europe in Pharmaceutical,
Investors in Europe in Therapeutics,
Investors in Europe in Health Care,
Investors in Europe in Medical

European Union (EU) (0 Investors) (0 Startups)

Founded date 12, 2007

Founders Renfeng Guo, Niels Riedemann

Operating Status Active

Funding Stage IPO

Last Funding Type Post-IPO Equity

Also known as InflaRx GmbH

Company Type For Profit


LinkedIN Link

Wikipedia Link

InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. In April 2018, InflaRx conducted a USD 117 million total gross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany.

Date Round Raised Lead
February, 25, 2021 Post-IPO Equity $75,000,000 -------
October, 13, 2017 Series D $55,000,000 Bain Capital Life Sciences, Cormorant Asset Management
July, 21, 2016 Series C $34,000,000 Staidson Hongkong Investment
July, 17, 2014 Series B Undisclosed bm-t beteiligungsmanagement thuringen
March, 18, 2009 Series A Undisclosed Affentranger Associates
March, 18, 2008 Seed Undisclosed Affentranger Associates

InflaRx Investors (8)

Investor Lead? Round Participating Raise Date Partners
Bain Capital Life Sciences Yes Series D $55,000,000 October, 13, 2017 -------
Cormorant Asset Management Yes Series D $55,000,000 October, 13, 2017 -------
RA Capital Management No Series D $55,000,000 October, 13, 2017 -------
Staidson Hongkong Investment Yes Series C $34,000,000 July, 21, 2016 -------
bm-t beteiligungsmanagement thuringen Yes Series B Undisclosed July, 17, 2014 -------
Affentranger Associates Yes Series A Undisclosed March, 18, 2009 -------
bm-t beteiligungsmanagement thuringen No Seed Undisclosed March, 18, 2008 -------
Affentranger Associates Yes Seed Undisclosed March, 18, 2008 -------